Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Wednesday, Citi analyst Geoff Meacham upgraded PTC (NASDAQ:PTC) Therapeutics (NASDAQ:PTCT) stock from Sell to Neutral, adjusting the price target to $40.00, a decrease from the previous target of $50.00. According to InvestingPro data, the stock’s relative strength index suggests oversold conditions, while analyst targets range from $40 to $113, indicating potential upside despite recent challenges. Meacham’s decision follows PTC Therapeutics’ first-quarter 2025 revenue report, which surpassed expectations. The company’s total revenue was reported at $190 million, $20 million higher than the consensus forecast by Bloomberg. This increase was partly attributed to stronger-than-anticipated sales of Emflaza, reaching $48 million, which is $8 million above projections. InvestingPro analysis shows the company generated $806.78 million in revenue over the last twelve months, though maintaining a healthy current ratio of 2.35, indicating strong short-term liquidity.
The company’s recent performance has been partially driven by Emflaza sales which exceeded anticipated volumes despite the expected erosion to biosimilars. The focus of investors has been on PTC Therapeutics’ recent data concerning PTC518 for Huntington’s disease, along with upcoming regulatory decisions for Sephience, for the treatment of PKU, and vatiquinone, aimed at addressing Friedreich’s ataxia.
Meacham pointed out that the 28% decline in the company’s stock value on Tuesday was a response to the latest Huntington’s disease data, which also suggests potential regulatory challenges for the PTC518 program. The analyst expressed skepticism about the program’s prospects for accelerated approval. However, he also noted that with the market’s expectations now more closely aligned with his assessments, there could be opportunities ahead as the company anticipates potential approvals and launches for Sephience and vatiquinone in the summer. These treatments target disease areas with significant unmet medical needs.
The analyst’s commentary highlighted the upcoming PDUFA date for Sephience, set for July 29, 2025, as a key event for PTC Therapeutics. The balance of risk and reward for the stock is now deemed more even, following the recent realignment of market expectations. While the company faces profitability challenges with a net loss of $363.3 million in the last twelve months, two analysts have recently revised their earnings expectations upward for the upcoming period, suggesting potential improvement ahead.
In other recent news, PTC Therapeutics reported first-quarter 2025 revenue of $190 million, surpassing the forecast of $167.54 million. This positive outcome was primarily driven by the company’s DMD franchise and royalty revenues, including $134 million from the DMD franchise and $36 million in Roche EVRYSDI royalty revenue. Despite these strong financial results, the company’s stock experienced a significant drop during regular trading hours, reflecting mixed investor sentiment. PTC Therapeutics also provided full-year revenue guidance of $650 to $800 million, indicating confidence in its product pipeline and market strategies. The company closed the quarter with over $2 billion in cash, supporting its commercial and R&D efforts. Additionally, the company is preparing for the anticipated global launch of SUFIANCE and continues discussions with regulatory authorities for pending approval applications. Analyst feedback was not explicitly mentioned, but the company’s financial position and strategic initiatives suggest a focus on growth and market expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.